NuVasive
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict NuVasive's revenues will grow 4.7% and EPS will drop -11.1%.
The average estimate for revenue is $161.7 million. On the bottom line, the average EPS estimate is $0.24.
Revenue details
Last quarter, NuVasive reported revenue of $159.5 million. GAAP reported sales were 5.2% higher than the prior-year quarter's $151.7 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS details
Last quarter, non-GAAP EPS came in at $0.26. GAAP EPS of $0.02 were the same as the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
Recent performance
For the preceding quarter, gross margin was 75.5%, 20 basis points worse than the prior-year quarter. Operating margin was 4.0%, 100 basis points worse than the prior-year quarter. Net margin was 0.5%, 10 basis points better than the prior-year quarter.
Looking ahead
The full year's average estimate for revenue is $656.3 million. The average EPS estimate is $1.01.
Investor sentiment
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 170 members out of 188 rating the stock outperform, and 18 members rating it underperform. Among 42 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 38 give NuVasive a green thumbs-up, and four give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on NuVasive is outperform, with an average price target of $21.71.
Is NuVasive the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add NuVasive to My Watchlist.
